Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
ZUG, Switzerland and CAMBRIDGE, Mass. and TÜBINGEN, Germany, and BOSTON, Nov. 13, 2017 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a genome editing company focused on creating...
-
Albany, New York, Nov. 13, 2017 (GLOBE NEWSWIRE) -- The global diabetes injection pens market is consolidated on account of the dominance of a few large players. The leading players within this...
-
CAMBRIDGE, Mass., Nov. 12, 2017 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe...
-
CAMBRIDGE, Mass., Nov. 10, 2017 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe...
-
NEW YORK, Nov. 10, 2017 (GLOBE NEWSWIRE) -- The global adhesion barrier market market is expected to witness a CAGR of 8.6%, and is projected to reach USD 1,512.9 million by 2023. The global...
-
GEREGLEMENTEERDE INFORMATIE GENT, België, 10 november 2017 - Ablynx [Euronext Brussels en Nasdaq: ABLX] maakte vandaag bekend, in overeenstemming met artikel 14 van de Belgische wet van 2 mei...
-
REGULATED INFORMATION GHENT, Belgium, 10 November 2017 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the...
-
Accord entre Sanofi et Principia pour le développement d'un candidat-médicament contre la sclérose en plaques L'accord porte sur un candidat-médicament par voie orale au stade du développement...
-
Sanofi, Principia agree to develop multiple sclerosis drug candidate Clinical-stage oral drug candidate (PRN2246) with the potential to treat multiple sclerosis Principia to receive $40...
-
GENT, België, 9 november 2017 - Ablynx [Euronext Brussels and Nasdaq: ABLX] meldt vandaag dat ze zal deelnemen aan de volgende investeerderscongressen die zullen doorgaan in Londen, VK en Parijs,...